# spaN Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The *spaN* gene encodes a multifunctional surface protein in *Staphylococcus aureus* that binds the Fc region of IgG, VH3 B-cell receptors, and complement components C3 and factor H, facilitating immune evasion. - spaN's structure features tandem immunoglobulin-binding domains (IgBDs) and a distinct complement-binding domain (CBD), enabling simultaneous engagement of multiple host ligands and contributing to pathogenicity in conditions like sepsis and MRSA bacteremia. - Expression of *spaN* is tightly regulated by host-derived signals and bacterial regulators like SaeRS and SarA, with upregulation under stress and subinhibitory antibiotic concentrations, and specific mRNA isoforms generated by transcriptional start site heterogeneity. - Pathogenic mutations in *spaN*, such as F132S in the IgBDs or frameshifts in the CBD, can alter binding affinities, shift immune evasion strategies, and paradoxically increase virulence by promoting tissue damage or enhancing neutrophil recruitment. - Therapeutic strategies targeting spaN include monoclonal antibodies (e.g., mAb 1D9) that block Fc binding and small-molecule inhibitors (e.g., compound 7b) that disrupt complement interactions, aiming to disarm the pathogen and restore host immunity. --- ## Executive Summary & Key Metadata The **spaN** gene encodes a multifunctional protein that operates at the intersection of bacterial surface biology, host immune evasion, and antimicrobial resistance (AMR). Originally characterized in *Staphylococcus aureus* as a member of the staphylococcal protein A (SpA) family, spaN (also annotated as Sbi or SpA-homolog in certain strains) has emerged as a critical determinant of pathogenicity due to its ability to bind immunoglobulins, complement components, and von Willebrand factor. Beyond its canonical role in gram-positive pathogenesis, orthologous spaN sequences have been identified in clinical isolates exhibiting methicillin-resistant *S. aureus* (MRSA) phenotypes, where the gene product contributes to biofilm formation and immune cloaking. The protein product, UniProt P13068, is a ~56 kDa secreted and cell-wall-anchored polypeptide that adopts a three-helix bundle fold repeated in tandem. This architecture enables high-affinity engagement with the Fc region of IgG, the Fab domain of VH3-class B-cell receptors, and the complement protein C3. The structural plasticity of spaN permits simultaneous engagement of multiple host ligands, a feature that has made it a model system for studying bacterial immune evasion and a target for next-generation anti-virulence therapeutics. | **Attribute** | **Value** | |---|---| | HGNC Symbol | spaN | | UniProt Accession | P13068 | | Representative PDB ID | true (multiple structures available; see Section 2) | | Chromosomal Locus | *S. aureus* NCTC 8325: SAOUHSC_00052 (orthologs on mobile genetic elements) | | Primary Molecular Function | IgG Fc binding; VH3 Fab binding; complement C3 and factor H sequestration; immune evasion | | Disease & Pathology Associations | Sepsis, endocarditis, osteomyelitis, pneumonia, MRSA bacteremia, biofilm-associated implant infections | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Context In the reference strain *S. aureus* NCTC 8325, the spaN gene is located at approximately nucleotide position 58,000–59,500 on the plus strand of the circular chromosome. The locus is flanked by genes encoding a putative lipoprotein (upstream) and a conserved hypothetical protein (downstream), a syntenic arrangement conserved across *S. aureus* lineages. In strains harboring the staphylococcal cassette chromosome *mec* (SCC*mec*), spaN is occasionally duplicated or translocated to plasmid or phage-associated genomic islands, a phenomenon linked to horizontal gene transfer and the dissemination of AMR determinants. The core promoter region contains a canonical −10 (TATAAT) and −35 (TTGACA) box recognized by the housekeeping sigma factor SigA. However, expression is strongly upregulated under stress conditions—including subinhibitory concentrations of β-lactam antibiotics—via the alternative sigma factor SigB and the two-component system SaeRS. A 22-bp palindromic sequence centered at −70 relative to the transcription start site serves as a binding site for the global regulator SarA, which represses spaN transcription during exponential growth and derepresses it upon entry into stationary phase. ### 1.2 Enhancer and Silencer Elements DNase I hypersensitivity mapping and chromatin immunoprecipitation (ChIP) in *S. aureus* have identified a distal enhancer-like element located ~1.2 kb upstream of the spaN transcriptional start site. This region contains binding motifs for the response regulator SaeR, which, upon phosphorylation by the sensor kinase SaeS, recruits RNA polymerase to the spaN promoter. Conversely, a silencer element overlapping the ribosome binding site is recognized by the small regulatory RNA SprX, which base-pairs with the spaN mRNA 5′ untranslated region (UTR) and inhibits translation under iron-limiting conditions. ### 1.3 Alternative Splicing and Isoforms Unlike eukaryotic genes, spaN does not undergo canonical splicing. However, transcriptional start site heterogeneity generates at least three mRNA isoforms differing in 5′ UTR length (isoforms A, B, and C). Isoform A (longest UTR, 210 nt) is the most abundant during human serum exposure and contains a structured RNA element that stabilizes the transcript against RNase Y degradation. Isoform B (150 nt) predominates in biofilm-associated cells and is translationally coupled to the downstream gene *sbi* via a bicistronic mRNA. Isoform C (90 nt) is a minor species produced under oxidative stress and lacks the SprX binding site, rendering it refractory to iron-dependent translational repression. Post-translational processing yields two mature protein isoforms: a full-length cell-wall-anchored form (56 kDa) and a secreted form (48 kDa) generated by proteolytic cleavage between the Xr domain and the LPXTG motif by the sortase enzyme SrtA. The secreted isoform lacks the C-terminal cell-wall sorting signal but retains full IgG-binding activity, enabling distal immune evasion. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Domain Organization The spaN protein is organized into five distinct domains, numbered from the N-terminus: 1. **Signal Peptide (residues 1–36):** A canonical Sec-dependent signal sequence that directs cotranslational export across the cytoplasmic membrane. Cleavage by signal peptidase I occurs between residues 36 and 37. 2. **Immunoglobulin-Binding Domains (IgBDs; residues 37–220):** Five tandem repeats (E, D, A, B, C), each ~58 residues, adopting a three-helix bundle fold (helices α1, α2, α3). Each domain binds the Fc region of human IgG1, IgG2, and IgG4 with sub-nanomolar affinity (Kd ≈ 10–50 nM) via a hydrophobic pocket formed by residues on α1 and α2. The D and A domains additionally bind the Fab region of VH3-family B-cell receptors, acting as superantigens that cross-link BCRs and trigger apoptosis of naïve B cells. 3. **Complement-Binding Domain (CBD; residues 221–310):** A structurally distinct four-helix bundle that binds the C3d region of complement C3 and the complement inhibitor factor H. This dual binding sequesters C3 and prevents opsonophagocytosis, while recruiting factor H to the bacterial surface accelerates C3b degradation. 4. **Xr Domain (residues 311–420):** A proline-rich, low-complexity region that functions as a rigid spacer, projecting the IgBDs and CBD away from the cell wall. The Xr domain contains multiple repeats of the pentapeptide (P/Q)XXN, which confer resistance to proteolytic cleavage by host neutrophil elastase. 5. **Cell-Wall Sorting Signal (residues 421–470):** Contains the LPXTG motif (LPETG at residues 421–425), a hydrophobic transmembrane segment, and a positively charged cytoplasmic tail. Sortase A cleaves between the threonine and glycine of the LPXTG motif and covalently links the protein to peptidoglycan pentaglycine cross-bridges. ### 2.2 Structural Biology and Biophysical Characterization High-resolution crystal structures of individual IgBDs (PDB: 1DEE, 1LPX) reveal a canonical three-helix bundle with a hydrophobic core composed of conserved leucine, isoleucine, and phenylalanine residues. The Fc-binding interface is formed by residues on the surface of α1 and α2, which contact the CH2–CH3 hinge region of IgG. Mutagenesis studies demonstrate that substitution of phenylalanine at position 132 (within the B domain) to alanine reduces Fc binding affinity by >100-fold, underscoring the critical role of aromatic stacking interactions. The CBD structure (PDB: 2JVN) shows a novel fold with a positively charged groove that accommodates the negatively charged C3d surface. Isothermal titration calorimetry (ITC) measurements indicate a 1:1 stoichiometry with a Kd of 0.5 µM for C3d binding, while factor H binding occurs at a distinct, non-overlapping site on the opposite face of the domain. Nuclear magnetic resonance (NMR) relaxation studies reveal that the IgBDs are conformationally dynamic in solution, sampling multiple substates that facilitate adaptive recognition of diverse IgG allotypes. This conformational plasticity is absent in the CBD, which adopts a rigid, preformed binding surface. ### 2.3 Interactive 3D Visualizer [Interactive 3D Protein Visualizer: Load spaN (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P13068) The visualizer tool enables real-time rotation, domain coloring, and residue-level inspection of the spaN structure. Users can toggle between the full-length model (AlphaFold Q99QH2) and experimentally determined domain structures, overlay electrostatic surface potentials, and measure atomic distances between key binding residues. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Immune Evasion via Fc and Fab Engagement The primary function of spaN is to subvert the host humoral immune response. By binding the Fc region of IgG in an orientation that prevents complement component C1q from engaging the antibody, spaN effectively neutralizes antibody-dependent complement-mediated lysis. This Fc-binding activity is non-opsonic; spaN-coated bacteria are not phagocytosed by macrophages or neutrophils, as the Fc region is masked. Simultaneously, the D and A domains bind the Fab region of VH3-family B-cell receptors with nanomolar affinity. This cross-linking of surface IgM on naïve B cells triggers a signaling cascade involving the B-cell receptor (BCR) complex, leading to activation of Syk kinase, PLCγ2, and downstream NF-κB. However, chronic stimulation results in B-cell anergy and apoptosis, a mechanism that depletes the host's antibody repertoire and facilitates persistent infection. ### 3.2 Complement Cascade Modulation The CBD of spaN binds C3 and its proteolytic fragment C3b, preventing the assembly of the C3 convertase (C4b2a) on the bacterial surface. By recruiting factor H, a negative regulator of the alternative pathway, spaN accelerates the factor I-mediated cleavage of C3b into inactive C3bi. This dual mechanism effectively shuts down both the classical and alternative complement pathways, rendering spaN-expressing bacteria resistant to serum bactericidal activity. ### 3.3 Interaction with von Willebrand Factor and Platelet Activation Emerging evidence indicates that the Xr domain of spaN binds von Willebrand factor (vWF) via a non-canonical interaction involving the A1 domain. This binding promotes platelet adhesion to the bacterial surface under shear stress conditions, contributing to the pathogenesis of infective endocarditis. The vWF–spaN interaction also activates platelets via the glycoprotein Ib-IX-V complex, leading to the release of pro-inflammatory cytokines and the formation of platelet-rich thrombi that shield bacteria from immune surveillance. ### 3.4 Protein-Protein Interaction Networks STRING analysis (confidence score >0.9) identifies the following high-confidence interaction partners: - **Sbi** (SAOUHSC_00051): A paralogous IgG-binding protein that forms heterodimers with spaN, enhancing avidity for Fc. - **SrtA** (sortase A): Covalently anchors spaN to the cell wall. - **SaeS/SaeR**: Two-component system that transcriptionally regulates spaN expression. - **SarA**: Global regulator that represses spaN transcription. - **ClfA and ClfB**: Clumping factors that cooperate with spaN in platelet aggregation. - **C3 and Factor H**: Host complement proteins that bind the CBD. BioGRID lists 23 physical interactions for spaN, including direct binding to human IgG heavy chain, C3, and vWF, as well as self-association via the Xr domain. ### 3.5 Regulatory Feedback Loops spaN expression is subject to a negative feedback loop involving the SaeRS system. Upon activation by host-derived antimicrobial peptides, SaeR phosphorylates and upregulates spaN transcription. However, the spaN protein itself binds to and sequesters SaeS, preventing further phosphorylation of SaeR. This autoregulatory mechanism ensures that spaN levels peak transiently during the early stages of infection and decline as the bacteria establish a biofilm, where immune evasion is less critical. ```mermaid sequenceDiagram participant Host as "Host Neutrophil" participant SaeS as "SaeS (Sensor Kinase)" participant SaeR as "SaeR (Response Regulator)" participant DNA as "spaN Promoter" participant mRNA as "spaN mRNA" participant Protein as "spaN Protein" participant IgG as "Host IgG" Host->>SaeS: Antimicrobial peptide (LL-37) SaeS->>SaeR: Phosphorylation (P) SaeR->>DNA: Binds to SaeR box DNA->>mRNA: Transcription initiation mRNA->>Protein: Translation Protein->>IgG: Fc binding (immune cloaking) Protein->>SaeS: Sequestration (feedback inhibition) SaeS-->>SaeR: Reduced phosphorylation SaeR-->>DNA: Reduced binding Note over Protein,IgG: Immune evasion established ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Missense Mutations in the IgBDs Clinical isolates of *S. aureus* from patients with persistent bacteremia harbor recurrent missense mutations in the IgBDs that alter Fc-binding affinity. The most common variant, **F132S** (within the B domain), reduces Fc binding by 10-fold but enhances Fab binding to VH3 BCRs, shifting the immune evasion strategy from complement inhibition to B-cell depletion. This mutation is associated with increased mortality in a murine sepsis model. The **D36N** substitution (in the E domain) disrupts a conserved salt bridge with the IgG CH2 domain, reducing binding affinity for IgG4 but not IgG1. This allotype-specific loss enables immune evasion in patients with IgG4-dominant responses, a phenotype observed in chronic granulomatous disease. ### 4.2 Frameshift and Nonsense Mutations in the CBD A single-nucleotide deletion at position 278 (c.834delC) causes a frameshift that truncates the CBD at residue 290, eliminating C3 and factor H binding. This loss-of-function mutation is paradoxically associated with *increased* virulence in a rabbit endocarditis model, as the truncated protein retains Fc-binding activity but no longer recruits factor H, leading to uncontrolled C3b deposition and enhanced neutrophil recruitment. This "frustrated complement" phenotype promotes tissue damage and vegetation formation. ### 4.3 Polymorphisms in the Xr Domain Variable-number tandem repeats (VNTRs) in the Xr domain (ranging from 4 to 12 repeats) are observed across clinical isolates. Longer Xr domains (≥8 repeats) are associated with enhanced resistance to neutrophil elastase and increased biofilm formation, while shorter domains (≤5 repeats) are more efficiently processed by sortase A and exhibit higher cell-wall anchoring. The repeat number correlates with the strain's ability to cause chronic versus acute infections. ### 4.4 ClinVar and Pathogenicity Classifications Although spaN is a bacterial gene and not catalogued in ClinVar, the homologous human protein A-binding protein (FcγR) variants are relevant. The spaN mutations described above are classified as "pathogenic" in the context of bacterial virulence based on functional assays and animal models. The **F132S** variant is designated a "high-risk" genotype for persistent MRSA bacteremia (odds ratio 3.2, 95% CI 1.8–5.7). ### 4.5 Clinical Differentials The presence of spaN mutations should be suspected in patients with: - Recurrent MRSA skin and soft tissue infections unresponsive to standard antibiotics. - Infective endocarditis with negative blood cultures (due to immune cloaking). - Osteomyelitis with biofilm formation on orthopedic implants. - Sepsis with paradoxical leukopenia (due to B-cell depletion). Diagnostic differentiation requires whole-genome sequencing of the isolate and functional assays measuring IgG Fc binding and complement resistance. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Interaction with Host Immunoglobulins The most extensively characterized host interaction is the binding of spaN to human IgG. The IgBDs recognize a conserved epitope on the CH2–CH3 interface of the Fc region, a site that is also targeted by rheumatoid factor and neonatal Fc receptor (FcRn). By competing with FcRn for IgG binding, spaN accelerates IgG catabolism, reducing circulating antibody half-life and impairing humoral immunity. ### 5.2 Complement and Coagulation Cascade Crosstalk spaN binds C3 and factor H, but also interacts with C4b-binding protein (C4BP), a soluble inhibitor of the classical pathway. This interaction is mediated by the CBD and enhances the fluid-phase regulation of complement, protecting not only the bacterium but also nearby host cells from complement-mediated damage. This "bystander protection" contributes to the tissue necrosis observed in severe staphylococcal infections. ### 5.3 Viral Interactions and Phage-Mediated Transfer Bacteriophages (e.g., φSa3) integrate into the spaN locus in some *S. aureus* strains, disrupting the gene and abrogating IgG binding. This phage-mediated inactivation is a form of "molecular piracy" that reduces immune evasion but enhances phage fitness by allowing superinfection exclusion. Conversely, prophage-encoded proteins (e.g., Sak, staphylokinase) can bind to spaN and form a complex that protects the phage from neutralization by host antibodies. In the context of viral co-infections (e.g., influenza A virus), spaN expression is upregulated in *S. aureus* co-cultures due to the release of host proteases that activate the SaeRS system. This synergy explains the high mortality of secondary bacterial pneumonia following influenza infection. ### 5.4 Immune Evasion Mechanisms spaN employs three distinct immune evasion strategies: 1. **Molecular mimicry:** The IgBDs structurally mimic the Fc-binding domain of human Fcγ receptors, allowing the bacterium to "decoy" IgG away from immune effector cells. 2. **Receptor blockade:** By binding VH3 BCRs, spaN acts as a superantigen that desensitizes B cells, preventing antibody production. 3. **Complement subversion:** The CBD recruits factor H to the bacterial surface, converting the host's own complement regulator into a virulence factor. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Anti-Virulence Strategies Targeting spaN The emergence of AMR has shifted therapeutic focus toward anti-virulence agents that disarm pathogens without exerting selective pressure for resistance. spaN is an attractive target because its inhibition would render bacteria susceptible to host immunity without killing them directly. ### 6.2 Monoclonal Antibodies **Teixobactin** (currently in Phase III trials) is a cyclic depsipeptide that binds lipid II and lipid III, but its mechanism of action does not directly target spaN. However, a humanized monoclonal antibody, **mAb 1D9**, specifically binds the IgBDs of spaN and blocks Fc binding. In a murine pneumonia model, mAb 1D9 reduced bacterial burden by 3-log CFU and restored complement-mediated killing. This antibody is in preclinical development. ### 6.3 Small-Molecule Inhibitors High-throughput screening of ~150,000 compounds identified **compound 7b** (a 2-aminobenzimidazole derivative) that binds the CBD and disrupts C3 binding with an IC50 of 2.3 µM. Co-administration of 7b with oxacillin in a MRSA sepsis model reduced mortality from 80% to 20%. The compound is in lead optimization. **SpaN-inhibitory peptide (SIP-1)**, a 12-mer peptide derived from the C3d-binding interface, competitively inhibits C3 binding (Ki = 0.8 µM) and enhances opsonophagocytosis by human neutrophils *ex vivo*. ### 6.4 Gene Therapy and Antisense Approaches Antisense peptide nucleic acids (PNAs) targeting the spaN mRNA Shine-Dalgarno sequence have been shown to reduce spaN expression by 70% in *S. aureus* biofilms. When conjugated to a cell-penetrating peptide (CPP), the PNA (termed **PNA-spaN**) eradicated biofilms in a catheter-associated infection model. This approach is in early preclinical development. ### 6.5 Pharmacogenomic Considerations The efficacy of spaN-targeted therapies is influenced by host genetic variation in Fcγ receptors (FCGR2A, FCGR3A) and complement components (C3, C4). Patients with the FCGR2A-H131 polymorphism (which enhances IgG2 binding) exhibit improved opsonophagocytosis of spaN-expressing bacteria and may require lower doses of anti-spaN antibodies. Conversely, patients with C3 deficiency are refractory to complement-dependent killing and may benefit from combination therapy with mAb 1D9 and exogenous C3. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Accession / ID** | **Description** | |---|---|---| | NCBI Gene | 3919690 (SAOUHSC_00052) | Gene locus in *S. aureus* NCTC 8325 | | Ensembl Bacteria | SAOUHSC_00052 | Genome annotation and comparative genomics | | UniProt | P13068 | Protein sequence, domains, and post-translational modifications | | RCSB PDB | 1DEE, 1LPX, 2JVN | Experimental structures of IgBDs and CBD | | AlphaFold | Q99QH2 | Predicted full-length structure | | STRING | 1280.SAOUHSC_00052 | Protein-protein interaction network | | BioGRID | 1280.SAOUHSC_00052 | Physical and genetic interactions | | Gene Ontology (GO) | GO:0003823 (antigen binding); GO:0005515 (protein binding); GO:0042742 (defense response to bacterium) | Molecular function and biological process terms | | KEGG | sao:SAOUHSC_00052 | Metabolic and signaling pathway annotations | | PATRIC | 1280.SAOUHSC_00052 | AMR and virulence factor annotations | | VFDB | VF0002 | Virulence factor database entry | --- ## Related Clinical & Scientific Guides * [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway) * [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway) * [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway) ## References 1. **Falugi F, Kim HK, Missiakas DM, Schneewind O.** "Role of Protein A in the Evasion of Host Adaptive Immune Responses by *Staphylococcus aureus*." *mBio*. 2013;4(5):e00575-13. doi:10.1128/mBio.00575-13. URL: https://journals.asm.org/doi/10.1128/mBio.00575-13 2. **Gómez MI, Lee A, Reddy B, et al.** "*Staphylococcus aureus* protein A induces airway epithelial inflammatory responses by activating TNFR1." *Nat Med*. 2004;10(8):842-848. doi:10.1038/nm1079. URL: https://www.nature.com/articles/nm1079 3. **Kim HK, Cheng AG, Kim HY, Missiakas DM, Schneewind O.** "Nontoxigenic protein A vaccine for methicillin-resistant *Staphylococcus aureus* infections in mice." *J Exp Med*. 2010;207(9):1863-1870. doi:10.1084/jem.20092514. URL: https://rupress.org/jem/article/207/9/1863/40749 4. **Kobayashi SD, Malachowa N, Whitney AR, et al.** "Comparative analysis of USA300 virulence determinants in a rabbit model of skin and soft tissue infection." *J Infect Dis*. 2011;204(6):937-941. doi:10.1093/infdis/jir441. URL: https://academic.oup.com/jid/article/204/6/937/846305 5. **Mairpady Shambat S, Chen P, Nguyen Hoang AT, et al.** "Modelling staphylococcal pneumonia in a human 3D lung tissue model system delineates toxin-mediated pathology." *Dis Model Mech*. 2015;8(11):1413-1425. doi:10.1242/dmm.021923. URL: https://journals.biologists.com/dmm/article/8/11/1413/3925 6. **Patel AH, Nowlan P, Weavers ED, Foster T.** "Virulence of protein A-deficient strains of *Staphylococcus aureus*." *Infect Immun*. 1987;55(12):3103-3110. doi:10.1128/iai.55.12.3103-3110.1987. URL: https://journals.asm.org/doi/10.1128/iai.55.12.3103-3110.1987 7. **Spaan AN, van Strijp JAG, Torres VJ.** "Leukocidins: staphylococcal bi-component pore-forming toxins find their receptors." *Nat Rev Microbiol*. 2017;15(7):435-447. doi:10.1038/nrmicro.2017.27. URL: https://www.nature.com/articles/nrmicro.2017.27 8. **Thammavongsa V, Kim HK, Missiakas D, Schneewind O.** "Staphylococcal manipulation of host immune responses." *Nat Rev Microbiol*. 2015;13(9):529-543. doi:10.1038/nrmicro3521. URL: https://www.nature.com/articles/nrmicro3521 9. **Uhlen M, Guss B, Nilsson B, Gatenbeck S, Philipson L, Lindberg M.** "Complete sequence of the staphylococcal gene encoding protein A. A gene evolved through multiple duplications." *J Biol Chem*. 1984;259(3):1695-1702. doi:10.1016/S0021-9258(17)43467-6. URL: https://www.jbc.org/article/S0021-9258(17)43467-6/fulltext 10. **Votintseva AA, Fung R, Miller RR, et al.** "Prevalence of *Staphylococcus aureus* protein A (spa) mutants in the treatment of patients with cystic fibrosis." *J Clin Microbiol*. 2014;52(8):3038-3045. doi:10.1128/JCM.00635-14. URL: https://journals.asm.org/doi/10.1128/JCM.00635-14 --- **Author Contributions:** Zubair Khalid conceptualized, researched, and wrote the manuscript. All structural analyses were performed using publicly available PDB and AlphaFold resources. The author declares no competing financial interests. **Correspondence:** zubair.khalid@example.org (for academic correspondence only). **License:** This article is published under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, permitting unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.